# A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

NCT05986292

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 2 |
| **Sponsor** | Eli Lilly and Company |
| **Enrollment** | 10,000 participants |

## Key Eligibility Criteria

### Inclusion (6)

- have a visual analog scale (VAS) pain value \>40 and \<95 at screening and prerandomization screening.
- have a history of daily pain for at least 12 weeks based on participant report or medical history
- have a value of d30 on the pain catastrophizing scale
- have a body mass index \<40 kilogram/square meter (kg/m²) (inclusive)
- are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.

... and 1 more (see full listing online)

### Exclusion (10)

- have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia
- have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)
- have surgery planned during the study for any reason, related or not to the disease state under evaluation.
- have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
- have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.

... and 5 more (see full listing online)

## Locations (63 total)

Central Research Associates, Birmingham, Alabama, United States
Simon Williamson Clinic, Birmingham, Alabama, United States
Synexus Clinical Research - Glendale, Glendale, Arizona, United States
... and 60 more locations